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Current psychopharmacological nomenclature remains wedded in an earlier period of scientiﬁc
understanding, failing to reﬂect contemporary developments and knowledge, does not aid
clinicians in selecting the best medication for a given patient, and tends to confuse patients by
prescribing a drug that does not reﬂect their identiﬁed diagnosis (e.g. prescribe “antipsycho-
tics” to depression). Four major colleges of Neuropsychopharmacology (ECNP, ACNP, Asian CNP,
and CINP) proposed a new template comprising a multi-axial pharmacologically-driven
nomenclature tested by four surveys. The template has ﬁve axes: 1—class (primary pharma-
cological target and relevant mechanism); 2—family (reﬂecting the relevant neurotransmitter
and mechanism); 3—neurobiological activities; 4—efﬁcacy and major side effects; and 5—
approved indications. The results of the surveys suggest that the clinicians found the available
indication-based nomenclature system dissatisfactory, non-intuitive, confusing, and doubt-
inducing for them and the patients. The proposed ﬁve-axis template seeks to upend current
usage by placing pharmacology rather than indication as the primary axes, with the proposed
nomenclature relating primarily to Axis 1—the class, and usage of the other axes would largelyo.2013.08.004
hed by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
/by-nc-nd/3.0/).
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Figure
J. Zohar et al.1006depend upon the extent to which the clinician seeks to deepen the scientiﬁc and clinical base of
his involvement. A signiﬁcant proportion of the participants in the four surveys were in favour
of the proposed system, a similar number wanted to consider the idea further, and only a small
proportion (8.6%) were against it. The proposed ﬁve-axis pharmacology based nomenclature
template is a system which might refresh and reﬂect the current scientiﬁc concepts of
neuropsychopharmacology.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Ideally, pharmacological nomenclature should embody con-
temporary scientiﬁc knowledge, help the clinician in making
an informed decision, and enhance patient adherence to
the treatment plan. Unfortunately, current psychiatric drug
classiﬁcation (Figure 1) fails to serve any of these purposes.
First, it does not reﬂect the advances in our knowledge.
Thus, for example, the terms “antidepressant” and “anti-
psychotic” were coined in the early 1950s in line with their
clinical use during that period—long before the relevant
neuroscience information was understood. The anachronis-
tic “antipsychotic” was even extended to “second genera-
tion antipsychotics”—a term that, despite its potential
marketing appeal, has no relation to current neuropsycho-
logical knowledge either of the psychotropic's relevant
modes of action or its potential clinical efﬁcacy.
The class to which a drug belongs reﬂects neither its relevant
neurotransmitter nor its mechanism of action and consequently
does not guide the clinician as to the full spectrum of disorders
it can be used to treat. The nomenclature employed by our
colleagues in hypertension, in contrast, identiﬁes the drug's
principal mode of action (see Table 1), thus guiding them
towards a combination of medications that address different1 Current antidepressant nommechanisms when seeking to augment the response to the
treatment.
Finally, the current nomenclature is also confusing to the
patients, as some of the “antipsychotics” are used to treat both
depression (e.g., quetiapine, olanzapine, etc.) (Bauer et al.,
2009; Thase et al., 2007; Berman et al., 2007) and anxiety
disorders (e.g., olanzapine and quetiapine) (Komossa et al.,
2010; Zohar and Allgulander, 2011), thus liable to cause patients
to become confused: “Why I am being prescribed an ‘anti-
psychotic’ when I am suffering from depression or anxiety”. “Is
my situation that bad, Doctor? Am I in danger of becoming
psychotic?” Under such circumstances, it is not difﬁcult to
understand that adherence to the course of medication pre-
scribed may be seriously compromised.
The term “antidepressant” fares little better. Many anti-
depressants are also employed as “anti-anxiety” medications
when the patient is not depressed (Zohar et al., 1987).
This is again likely to be confusing and/or worrisome for
the patient: “Why am I given antidepressants if I am not
depressed?”
The present contributors also contend that, just as
updates are constantly sought with respect to diagnosis
(DSM III, IV, 5, ICD 9, 10, 11, etc.), similar adjustments to
pharmacology nomenclature should be sought.enclature under the WHO system.
Table 1 Classes of medication in the treatment of
hypertension.
Class name General characteristics
Diuretics Reduce excess sodium and
water, thereby controlling
blood pressure.
Beta-blockers Reduce heart rate and heart
workload, and its blood output.
ACE (angiotensin-
converting enzyme)
inhibitors
Reduce production of
angiotensin, thereby
facilitating the relaxation and
dilation of blood vessels, in turn
lowering blood pressure.
Angiotensin II receptor
blockers
Block the effects of
angiotensin, a peptide hormone
that stimulates arterial
constriction.
Calcium channel
blockers
Prevents calcium from entering
the smooth muscle cells of the
heart and arteries, thereby
relaxing and dilating
constricted blood vessels.
Alpha blockers Reduce resistance of the
arteries, thus relaxing the
muscle tone of the vascular
walls.
Alpha-2 receptor
agonists
Decrease activity of the
sympathetic (adrenaline-
producing) region of the
involuntary nervous system.
Central agonists Help decrease constriction of
blood vessels.
Peripheral adrenergic
inhibitors
Reduce blood pressure by
blocking neurotransmitter
receptors in the brain.
Blood vessel dilators/
vasodilators
Cause the muscles in the walls
of the blood vessels (especially
the arterioles) to relax,
allowing the vessel to dilate.
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psychiatric pharmacological brief—the European College of
Neuropsychopharmacology (ECNP), the American College of
Neuropsychopharmacology (ACNP), the Collegium Internatio-
nale de Neuropsychopharmacologie (CINP), and the Asian
College of Neuropsychopharmacology (AsCNP)—determined
that the time had come to meet the nomenclature challenge.
In collaboration with the International Union of Basic and
Clinical Pharmacology (IUPHAR), they established a taskforce
with the mission of updating and formulating pharmacologi-
cal nomenclature relevant to brain disorders. Although the
goal was to produce a template according to which existing
compounds could be reclassiﬁed and new compounds intro-
duced, it was acknowledged that, in the case of novel
medications, the formation of a new class might be justiﬁed.
A multi-axial, pharmacologically-driven nomenclature was
subsequently developed, with regard to which four ﬁeld testswere conducted. The following section presents the multi-
axial template and the results of the ﬁeld tests.
2. Experimental procedures
2.1. Developing the multi-axial template
Following a series of meetings between representatives of the four
organizations (JZ and DJN for ECNP; DJK for ACNP; SMS and HJM for
CINP; SY for AsCNP; and MS for IUPHAR) and consultation with
colleagues and pharmaceutical company representatives, the fol-
lowing multi-axial template was developed (Table 2).
Axis 1 identiﬁes the primary pharmacological target and the
mechanism. Axis 2 lists its family, reﬂecting the primary neurotrans-
mitter and relevant mechanism. Axis 3 relates to the drug's known
neurobiological activities, including its neurotransmitter effects,
brain circuits, and physiological effects (in both humans and animals).
Axis 4 details the clinical observations, including the drug's major
known efﬁcacy and side effects. Axis 5 includes only current approved
indications. Additionally, as an end-note of some tables (when
appropriate) another feature coined “Committee Note” will be
added. The Committee Note will include information about potential
new indication and other ‘clinical pearls’.2.2. Testing the multi-axial template
Four ﬁeld tests designed to examine the potential acceptance and
efﬁcacy of the proposed system were conducted. The ﬁrst was
carried out in September 2011 in Paris at the annual ECNP meeting.
This trial included 371 respondents: 286 (77%) psychiatrists, 22 (6%)
brain researchers, 19 (5%) pharmacologists, 7 (2%) psychologists,
and 41 (11%) “other”. Responses were obtained via feedback from a
keypad system that allowed each of the 371 participants to express
his/her opinion anonymously, free of group or peer pressure.
The second survey was conducted in Prague at the annual EPA
meeting (March 2012). On this occasion there were 80 respondents,
including 59 (74.2%) psychiatrists, 7 (9.1%) brain researchers, 2 (3%)
psychologists/neurologists, and 11 (13.6%) “other”. Here, too,
responses were obtained via feedback using a keypad system.
The third survey was conducted in February 2012 via an internet
questionnaire and included 455 participants: 252 (55.4%) psychia-
trists, 24 (5.3%) psychologists, 8 (1.8%) pharmacologists, 3 (0.7%)
neurologists, 2 (0.4%) brain researchers, and 166 (36.5%) “other”.
The fourth survey was conducted in October 2012 at the ECNP's
Twenty-Fifth Annual Congress in Vienna. 326 delegates partici-
pated, of whom 245 (75.1%) were psychiatrists, 22 (6.7%) brain
researchers, 6 (1.8%) psychologists, 2 (0.6%) neurologists, and 32
(9.8%) “other”.
The surveys conducted at the three Congresses (ECNP Paris and
Vienna and EPA in Prague) were based on questions asked during a
session dedicated to the nomenclature initiative. For the fourth
survey, US practitioners were directed via one of the author's (SMS)
website to an e-survey site, where they were asked to respond to the
questions presented in the same order as at the Congresses. In total,
responses were received from 1232 participants: 842 (68%) psychia-
trists, 53 (4.3%) brain researchers, 45 (3.7%) pharmacologists, 37 (3%)
psychologists, 7 (0.6%) neurologists, and 250 (20.3%) “other”.
The questions asked are presented in Table 3 and relate to four
areas:1) Relevant characteristics (Questions 1–2).
2) Current practice and knowledge (Questions 3–6).
3) Feedback regarding nomenclature dilemmas (Questions 11–17).
4) Response to the proposed nomenclature following the proposal
of the multi-axial concepts (Questions 18–22).
Table 2 Proposed template for a multi-axial psychopharmacological nomenclature.
Axis 1 Class (primary pharmacological target)
Relevant mechanism
Axis 2 Family (primary neurotransmitter(s) and relevant mechanism)
Axis 3 Neurobiological activities
Animal Human
Neurotransmitter effects
Brain circuits
Physiological
Axis 4 Efﬁcacy and major side effects
Axis 5 Indications
Committee Note:
Table 3 Questions used in the ﬁeld tests of the proposed multi-axial nomenclature template.
Question Response options
1 How many patients do you see yearly? – More than 10
– Less than 10
– I don't see any patients
2 Are you a – Psychiatrist
– Neurologist
– Psychologist
– Brain researcher
– Other
3 Have you heard of WHO categories of drug classes? – Yes
– No
4 What class are antidepressants listed as in WHO system? – Analeptic
– Antidepressant
– Psychoanaleptic
– Psychostimulant
– Thymoleptic
5 Does the current classiﬁcation of antidepressant drugs into
SSRIs, SNRIs etc. affect your prescribing practice? Do you
consider the different classes to have signiﬁcant and so clinically
relevant differences?
– Yes
– No
– Don't know
6 Which factor do you think of ﬁrst when you are deciding which
antidepressant to use?
– Pharmacology
– Pharmacokinetics
– Cost
– Adverse effects
7 If SSRI=Selective serotonin reuptake inhibitor, what should SNRI
mean?
– Selective noradrenaline reuptake inhibitor
– Serotonin non-selective reuptake inhibitor
– Serotonin noradrenaline reuptake inhibitor
8 NaSSAs are – Noradrenaline and serotonin receptor antagonists
– Noradrenaline antihistamine and serotonin selective
antagonists
– Noradrenaline and selective serotonin receptor
antagonists
– Noradrenaline and serotonin speciﬁc antidepressant
– Noradrenaline and selective serotonin antagonists
9 What is psycholeptic? – Title of the latest song from Lady Gaga
– The ofﬁcial term for an antipsychotic by FDA
– The ofﬁcial term for an antipsychotic by WHO
– The ofﬁcial term for an antipsychotic by FDA
and WHO
10 Which organisations adopt each other's terminology for
antipsychotics?
– WHO
– APA
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Table 3 (continued )
Question Response options
– FDA
– EMA
– USP
– ACNP/ECNP/CINP
– AsCNP
– All of the above – None of the above
11 Which term do you prefer for the new antipsychotics? – Second-generation antipsychotic
– Atypical antipsychotic
– Serotonin dopamine agonist
– Other
12 Given that some antipsychotics are also approved as antimanics
and as antidepressants, do you think your preferred term for the
new antipsychotics is:
– Adequate/acceptable
– Confusing/inadequate
13 How should the new antipsychotics be classiﬁed? – By clinical use (i.e., antipsychotic, mood stabilizer,
antidepressant) even if one drug is in more than
one class
– By their principal shared mechanism of action
– By their functional neurobiological effect
– By their symptom improvement proﬁle
– If possible, all the above
14 What would you prefer for drugs with multiple targets of action? – Multifunctional
– Multimodal
– Mixed action
– Dirty
– Rich pharmacology
15 For agents that improve psychosis but also have other clinical
actions, should we use
– A pharmacological term, such as serotonin dopamine
antagonist, or 5HT2C antagonist, etc.
– A clinical term such as antipsychotic, antimanic,
antidepressant
– Other
16 If more than one term applies to a single molecule, such as
‘serotonin dopamine antagonist, plus serotonin 1A partial
agonist’, or ‘antipsychotic/antimanic/antidepressant’, to
include one molecule in several classes or to give one molecule
more than one name would be
– Helpful, agree that this should be done
– Confusing, disagree that any agent should be
classiﬁed in more than one way
– Don't know
17 How should a drug that improves just negative symptoms of
schizophrenia but does not block D2 receptors be categorized?
– As an antipsychotic
– As a negative symptoms antipsychotic
– By its pharmacologic action (e.g., glycine reuptake
inhibitor, etc.)
– Something else
18 What should we call vilazodone (Viibryd), the new
antidepressant with serotonin reuptake blocking and serotonin
1A partial agonist properties?
– SSRI
– Antidepressant
– Serotonin partial agonist reuptake inhibitor (SPARI)
– Something else
19 What should we call a selective glycine reuptake inhibitor that
has evidence of efﬁcacy in schizophrenia?
– Negative symptoms antipsychotic
– Antipsychotic
– Selective glycine reuptake inhibitor (SGRI)
– Glycine reuptake inhibitor (GRI)
– Glycine type 1 reuptake inhibitor
– Something else
20 What should we call agomelatine (Valdoxan), the new
antidepressant with melatonin 1 and 2 agonist, 5HT2C
antagonist properties that increase dopamine and
norepinephrine in the prefrontal cortex?
– Melatonergic antidepressant
– Melatonergic agonist, 5HT2C antagonist
– Melatonergic NDDI (norepinephrine and dopamine
disinhibitor)
– Something else
21 What should we call Lu21004, the agent with preliminary
evidence of antidepressant action with 6 actions: serotonin
reuptake inhibition, 5-HT1A partial agonism, and 5-HT3, 5-HT7,
– SSRI
– Antidepressant
– Multifunctional neurotransmitter enhancer
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Table 3 (continued )
Question Response options
and 5-HT1B/D antagonism that increases 5 neurotransmitters:
serotonin, norepinephrine, dopamine, acetylcholine, and
histamine?
– Multimodal neurotransmitter enhancer
– Something else
22 What are your ﬁrst thoughts on the multi-axial nomenclature of
psychotropics?
– Fully support
– Not yet sure
– Disagree
4This question was not asked at the ECNP survey in Vienna.
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A total of 1232 participated in the four surveys. Due to
technical limitations, some questions were not posed in
all four surveys. This is noted below when reporting the
results of the relevant questions. For the entire sample,
842 (68.3%) respondents were psychiatrists, the remainder
being neurologists (n=7, 0.6%), psychologists (n=37, 3.0%),
pharmacologists (n=45, 3.7%), brain researchers (n=53,
4.3%), or “others” (n=250, 20.3%). The majority of the
respondents (993, 80.6%) saw patients on a regular basis,
some (238, 19.3%) not seeing any or only a few a year.
The EPA and ECNP Vienna surveys also asked participants
about prescribing practices (n=406): 252 prescribed medi-
cation to over 70% of their patients (62.1% of all respon-
dents or 80.7% of those who saw patients). A summary of
the respondents’ background characteristics is presented in
Table 4.
When asked about their practice and knowledge of the
current nomenclature system, 772 (62.7%) respondents had
not heard of the WHO drug-class categories, only 368 (29.9%)
were aware that the WHO categorizes antidepressants as
“thymoleptics”. 1043 (84.7%) acknowledged that the classiﬁ-
cations of SSRI and SNRI affected their prescription choice.
The majority (64%) claimed that pharmacology formed the
principal factor in deciding which antidepressant to prescribe,
the second most prevalent consideration being adverse events
(24.8%). When asked to speculate what SNRI should stand for
based on SSRI as standing for “Selective Serotonin Reuptake
Inhibitor”, 826 (67.0%) contended that the present title—
Serotonin-Noradrenaline Reuptake Inhibitor—is the obvious
choice. 356 (28.9%) conceded that, based on the precedent
set by SSRI, SNRI should actually stand for “Selective Nora-
drenaline Reuptake Inhibitor”. Confusion was especially pro-
nounced regarding NaSSA, with responses more or less equally
distributed across the options. Only 21.3% correctly chose
“noradrenergic and speciﬁc serotonergic antidepressants”.2
680 respondents3 (59.0%) maintained that ofﬁcial WHO term
for an antipsychotic is psycholeptic (the correct answer).
94 (8.2%) thought the term was an FDA formulation,
319 (27.7%) believing the two bodies to be jointly responsible
for the terminology. 521 (56.5%) respondents thought that one
or more of the psychiatric and drug agencies adopt one
another's terminology for antipsychotics, less than half (506,
43.9%) were aware that they do not.
With respect to feedback regarding nomenclature dilem-
mas, respondents were divided as to whether the new2This question was not asked at the ECNP survey in Vienna.
3Not including the EPA survey.antipsychotics should be called second-generation antipsy-
chotics (23.5%), atypical antipsychotics (31.6%), serotonin
dopamine antagonists (29.9%), or another term (15.1%).
In light of the frequent use of some “antipsychotics” as
“anti-manics” and “antidepressants”, 826 (71.7%) agreed
that the terminology was inadequate or confusing. 398
(34.5%) respondents preferred a classiﬁcation of antipsy-
chotics based on the speciﬁc drug's principal shared
mechanism of action vs. 427 (37.1%) who preferred a
classiﬁcation based on several characteristics—their clinical
use, functional neurobiological effect, and symptom-
improvement proﬁle—if and when possible.
The ﬂoor feedback regarding drugs with multiple targets
of action was split between multifunctional (26.3%), multi-
modal (42.8%), and mixed action (25.3%).4 With respect to
agents that mitigate psychotic symptoms along with other
clinical actions, the highest preference was for a
pharmacologically-driven (51.9%) rather than a clinical-
based term (24.8%) or other option (20.6%). When a single
molecule can be deﬁned by more than one name, respon-
dents felt that placing it in more than one class or giving it
more than one name would be helpful (74.3%). Finally, 797
(64.7%) of the participants felt that a drug that mitigate
negative symptoms in schizophrenia but does not block D2
receptors should be categorized primarily by its pharmaco-
logical action.
Response to the proposed multi-axial nomenclature was
tested by taking speciﬁc drugs as examples. Participants
were ﬁrst asked about vilazodone (Viibryd), a new antide-
pressant with serotonin reuptake blocking and serotonin 1A
partial agonist properties (Table 5).5 The consensus was that
this agent should be classiﬁed under the “serotonin partial
agonist reuptake inhibitor” (SPARI) family (73.4%) rather than
SSRI (3.7%), antidepressant (8.5%), or ‘something else’
(14.3%). When asked what name they would choose for a
selective glycine reuptake inhibitor evidencing efﬁcacy in the
treatment of schizophrenia (Table 6),3 the majority (58.3%)
preferred the term “selective glycine reuptake inhibitor”
(SGRI) over “negative symptoms antipsychotic” (5.0%), anti-
psychotic (3.8%), glycine reuptake inhibitor (18.7%), glycine
type 1 reuptake inhibitor (10.5%), or ‘something else’ (3.2%).
The preferred term for agomelatine (Valdoxan)—an anti-
depressant with melatonin 1 and 2 agonist and 5HT2C
antagonist properties that increases dopamine levels in theN=906.
5Participants were not asked about this compound at the EPA
survey. N=1152.
Table 4 Summary of the survey respondents' background characteristics.
Characteristic Response ECNP Paris 2011
(n=371)
EPA Prague 2012
(n=80)
US Web Survey 2012
(n=455)
ECNP Vienna 2012
(n=326)
Total
(n=1232)
Profession Psychiatrist 77% 74.2% 55% 75.1% 68.3%
Neurologist 0% 3.0% 0.7% 0.6% 0.6%
Psychologist 2% 5.3% 1.8% 3.0%
Pharmacologist 5% 0.0% 1.8% 5.5% 3.7%
Brain researcher 6% 9.1% 0.4% 6.7% 4.3%
Other 11% 13.6% 36.5% 9.8% 20.3%
Patients seen
per year
More than 10 72% 61.5% 92.3% 78.8% 80.6%
Less than 10 8% 14.3% 4.2% 21.2% 10.5%
Don't see
patients at all
20% 24.3% 3.5% (Option not given) 8.8%
Table 5 vilazodone. Multi-axial psychopharmacological nomenclature for vilazodone.
Axis 1 Class serotonin
Relevant mechanism: reuptake inhibitor and receptor antagonist
Axis 2 Family
serotonin reuptake inhibitor and 5-HT1A partial agonist
Axis 3 Neurobiological activity
Animal Human
Neurotransmitter
effects
Increases extracellular levels of 5-HT in
frontal cortex and hippocampus; No effect on
norepinephrine levels
Brain circuits Preferential activation of cell body 5-HT1A
autoreceptors than postsynaptic 5-HT1A
receptors
Binds to 5-HT reuptake sites; Binds preferentially
to cell body 5-HT1A autoreceptors than
postsynaptic 5-HT1A receptors
Physiological Does not produce a 5-HT syndrome but
attenuates it when triggered by a potent
5-HT1A agonist
Marked REM suppression, slow wave sleep
increased
Axis 4 Efﬁcacy and major side effects
Anxiety symptoms; May produce signiﬁcant nausea upon treatment initiation; discontinuation syndrome
Axis 5 Approved indications
Major depressive disorders (USA) Committee notes Gradually decrease upon discontinuation
Committee Note: Gradually decrease upon discontinuation.
1011A proposal for an updated neuropsychopharmacological nomenclatureprefrontal cortex and norepinephrine in the prefrontal cortex
and hippocampus (Table 7)—was melatonergic agonist and
5HT2C antagonist (47.1%), melatonergic antidepressant gain-
ing a 17.8% vote, melatonergic NDDI (norepinephrine and
dopamine disinhibitor) a 28.1% vote, and ‘something else’ a
7.5% vote.6 Finally, respondents were asked about vortioxetine
(Lu AA21004), an investigational antidepressant thought to
work through a combination of two complementary mechan-
isms of actions—receptor activity modulation and reuptake
inhibition. In vitro studies indicate that vortioxetine is a 5-HT3,
5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial
agonist, 5-HT1A receptor agonist, and inhibitor of the 5-HT
transporter (Bang-Andersen et al., 2011; Westrich et al.,
2012). In vivo preclinical studies have demonstrated that6This compound was not adduced at the EPA or the ECNP Vienna
surveys.vortioxetine enhances the levels of 5 neurotransmitters: ser-
otonin, noradrenaline, dopamine, acetylcholine, and hista-
mine in speciﬁc areas of the brain (Mørk et al., 2012)
(Table 8).7 The majority preferred the term “multimodal
neurotransmitter enhancer” (58.9%) over SSRI (5.2%), anti-
depressant (5.3%), multifunctional neurotransmitter enhancer
(25.2%), or ‘something else’ (9.5%).3.1. Response to the multi-axial nomenclature
Overall, the response to the multi-axial nomenclature
proposal presented at the meetings was that the current
nomenclature clearly needs to be updated. When asked7Participants were not asked about this compound at the EPA
survey.
Table 6 bitopertin. Multi-axial psychopharmacological nomenclature for bitopertin.
Axis 1 Class glycine
Relevant mechanism: reuptake inhibitor
Axis 2 Family
Selective glycine reuptake type 1 (Glyt1) inhibitor
Axis 3 Neurobiological activity
Animal Human
Neurotransmitter
effects
Increased synaptic and CSF glycine level (1,2) (Alberati et al., 2012) Increased CSF glycine levels
(Pizzagalli et al., 2012)
Brain circuits Decreases DA release from the mid-brain to the striatum (1).
Enhances working memory in the prefrontal cortex in
primates (3) (Borroni et al., 2011)
Unknown
Physiological Social withdrawal in (ongoing) rodent studies. Enhancement
of NMDA receptor Dependent LTP rat hippocampus slice.
Axis 4 efﬁcacy and major side effects
negative symptoms of schizophrenia—especially social and emotional withdrawal in patients with persistent,
predominant negative symptoms—when used adjunctively with antipsychotic therapy.
Axis 5 approved indications
Committee Note: In Phase III, for schizophrenia for both indications: negative symptoms and sub-optimally controlled increases the
concentration of glycine in the synaptic cleft by blocking its reuptake through the GlyT1, glutamate action is enhanced at the NMDA
receptor—glycine being a co-agonist at this site.
J. Zohar et al.1012their opinion regarding the proposed multi-axial system, a
signiﬁcant proportion (45.2%) was in favour, a similar
number (46.1%) wanting more time to consider the idea.
Only a small proportion (8.6%) disagreed.4. Discussion
The multi-axial proposal for a new neuropsychopharmaco-
logical nomenclature is based on a ﬁve-axis template that
attempts to embody and reﬂect contemporary neuroscience
knowledge and insights. The new concepts in this nomen-
clature may help the clinician in making informed thera-
peutic decisions, as well as providing more logical messages
to patients regarding the scientiﬁc rationale of their
treatment.
One of the intentions of the proposed nomenclature is to
harness contemporary knowledge in neuroscience to the service
of therapeutic decisions i.e. augmentation, combination etc.
Although it is not intended to promote off-table use of
psychotropic it provides better tools to examine more sophis-
ticated use of our pharmacological armamentarium in
personalized-based approach, base of the domain prism, which
is imbedded in the proposed template.
In order for it to be utilized, the ﬁve-axis template
should be applied to both existing medications and new
drugs. Once in place, continued use will establish it as a
clear, helpful, and intuitive classiﬁcation system for psycho-
tropic medications.
The results of the four surveys demonstrate the inherent
limitations of the available indication-based nomenclature
for clinicians. This has resulted in referral to drugs by the
ﬁrst indication awarded—despite its other subsequently-
approved usages (e.g., “antidepressants” used to treat
anxiety disorders and OCD or “antipsychotics” prescribedfor treatment-resistant depression, tic disorders, and some
anxiety disorders). Such a practice is not only non-intuitive,
confusing, and doubt-inducing for the prescribing clinicians
but also causes confusion and thus non-adherence in
patients who ﬁnd it difﬁcult to accept that the medication
they have been prescribed belongs to a class designed to
treat a different disorder.
Perhaps not coincidentally, this attempt to update psy-
chiatric drug nomenclature accompanies and complements
another evolution in psychiatry. Recently, efforts have been
invested in identifying endophenotypes of psychiatric dis-
eases—i.e., cognitive and biological markers not readily
measurable at a clinical level that are speciﬁc to, and
indicative of, the disorder (Insel et al., 2010). Here, too,
the focus lies on the underlying pathology (endophenotype)
rather than the surface symptoms (phenotype).
The current proposal has its weaknesses which include
lack of sufﬁcient knowledge of actual mechanism of action
of drugs used in psychiatry and how their pharmacological
mechanism relates to clinical action. This is true speciﬁcally
for Axis 1 and 2. However, the suggested nomenclature does
reﬂect the contemporary knowledge as well as the progress
in neuroscience since the present classiﬁcation has been
made.
Another weakness is that the proposed nomenclature
might be viewed as complicated and cumbersome and
hence it may prove insufﬁciently practical and challenging
in gaining clinical acceptance. The four surveys go some way
to addressing this issue. Despite the limitations of the
system used—a keypad system on three occasions and e-
voting in one case—the overall majority of the responders
(many of whom see patients and prescribe medication on a
regular basis) supported the proposed nomenclature. This
endorsement appears to derive from two sources: (a) a clear
dissatisfaction with the current system; and (b) an evident
Table 7 Name: agomelatine. Multi-axial psychopharmacological nomenclature for agomelatine
Axis 1 Class melatonin serotonin
Relevant mechanism: receptor agonist and antagonist
Axis 2 Family
melatonin type 1 and type 2 receptor agonist serotonin 5-HT2C receptor antagonist
Axis 3 Neurobiological activity
Animal Human
Neurotransmitter
effects
Increases extracellular dopamine (DA) and
norepinephrine (NE) in the rat prefrontal cortex
and hippocampus; no effect on DA in the
nucleus accumbens
Unknown
Brain circuits Modiﬁes suprachiasmatic nucleus function;
increases DA activity in the mesolimbic and
mesocortical pathways
Prefrontal cortex, hippocampus, amygdala
(fMRI)
Physiological Increases DA transmission to the dorsal raphe
5-HT neurons; increases 5-HT ﬁring and 5-HT1A
transmission in the hippocampus; reverses the
decrease of neurogenesis produced by prenatal
stress; resynchronisation of circadian rhythms;
increased neuroplasticity
Phase advance of circadian rhythms. No change
in sleep architecture, in particular no increase
in slow wave sleep as expected with 5HT2
antagonists.
Axis 4 efﬁcacy and major side effects
anxiety symptoms; rare cases of transient elevation of hepatic enzymes; Little effect on sexual function
Axis 5 approved indications
Major depressive disorder
Committee Note: Rare cases of hepatic failure. A synergy between melatonergic agonist and 5HT2C antagonist actions is believed to
exist. GAD indication under regulatory review.
Table 8 vortioxetine. Multi-axial psychopharmacological nomenclature for vortioxetine
Axis 1 Class serotonin
Relevant mechanism: reuptake inhibitor, receptor antagonist and partial agonist
Axis 2 Family
Multimodel drug: Serotonin reuptake inhibitor, 5-HT3, 5-HT7, 5-HT1D receptor antagonist, 5-HT1A and 1B receptor
partial agonist
Axis 3 Neurobiological activity
Animal Human
Neurotransmitter
effects
Increases 5-HT Occupies SERT in raphe
nucleus (PET)NA, DA, and ACh in ventral hippocampus and prefrontal cortex
Histamine in medial prefrontal cortex
5-HT in nucleus accumbens
Brain circuits Increases cortical neurotransmitter activity via disinhibition of the
raphe nucleus and peripheral 5-HT receptors
Physiological Suppresses REM sleep
Axis 4 efﬁcacy and major side effects
Improves cognitive dysfunction in depression
Axis 5 approved indications
Major depressive disorders
1013A proposal for an updated neuropsychopharmacological nomenclaturedesire to harness pharmacological insights to the prescrip-
tion process.
A major task for a proposed nomenclature is to see how it
integrates with (rather than replaces) current acceptedsystems such as the European Drug Index (EDI) and the
Anatomical, Therapeutic Chemical (ATC) classiﬁcation. The
proposed nomenclature is actually in line with ATC as it
includes a therapeutics component (Axis 4 and 5) and a
J. Zohar et al.1014chemical component (Axis 1, 2 and 3). Furthermore, being
more elaborate, the ﬁve-axis template adds useful informa-
tion for the clinicians.
The change—and the challenge—posed by the new
nomenclature is that of turning the current nomenclature
upside down; the indications driving the existing nomen-
clature dropping to Axis 5 and pharmacology being placed at
the top of the list. While the ﬁve-axis system is convoluted
and unwieldy, routine use might be based primarily on Axis 1
(the class). Moving to other axes is optional—dependent to a
large extent on how far the clinician wishes to pursue the
speciﬁc clinical situation facing him. However, the choice of
psychotropic drug ideally should encompass the data pre-
sented in all axes yet with careful references to Axis 5
(approved indication).5. Conclusion
The need to update the current classiﬁcation in order to
reﬂect the contemporary knowledge in neuropsychophar-
macology is clear to researchers and clinicians alike. A ﬁve
axises system which focuses on pharmacology rather than
indication is proposed.Role of the funding source
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